Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) - Total Liabilities

Latest as of June 2025: $140.71 Million USD

Based on the latest financial reports, Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) has total liabilities worth $140.71 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Zhengye Biotechnology Holding Limited Or to evaluate the company's liquid asset resilience ratio.

Zhengye Biotechnology Holding Limited Ordinary Shares - Total Liabilities Trend (2021–2025)

This chart illustrates how Zhengye Biotechnology Holding Limited Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ZYBT asset base.

Zhengye Biotechnology Holding Limited Ordinary Shares Competitors by Total Liabilities

The table below lists competitors of Zhengye Biotechnology Holding Limited Ordinary Shares ranked by their total liabilities.

Company Country Total Liabilities
Nano X Imaging Ltd
NASDAQ:NNOX
USA $19.46 Million
Poujoulat S.A.
PA:ALPJT
France €215.04 Million
HBR Realty Empreendimentos Imobiliários S.A
SA:HBRE3
Brazil R$2.25 Billion
PTL Enterprises Limited
NSE:PTL
India Rs2.26 Billion
Donkeyrepublic Holding AS
CO:DONKEY
Denmark Dkr77.40 Million
Chin Well Holdings Bhd
KLSE:5007
Malaysia RM71.01 Million
Croda International PLC
LSE:CRDA
UK GBX1.23 Billion
NexLiving Communities Inc
V:NXLV
Canada CA$322.80 Million

Liability Composition Analysis (2021–2025)

This chart breaks down Zhengye Biotechnology Holding Limited Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Zhengye Biotechnology Holding Limited Or balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.31 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.50 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.29 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Zhengye Biotechnology Holding Limited Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Zhengye Biotechnology Holding Limited Ordinary Shares (2021–2025)

The table below shows the annual total liabilities of Zhengye Biotechnology Holding Limited Ordinary Shares from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 $140.71 Million 0.00%
2024-12-31 $140.71 Million -12.40%
2023-12-31 $160.62 Million -1.35%
2022-12-31 $162.81 Million +28.76%
2021-12-31 $126.44 Million --

About Zhengye Biotechnology Holding Limited Ordinary Shares

NASDAQ:ZYBT USA Drug Manufacturers - Specialty & Generic
Market Cap
$64.93 Million
Market Cap Rank
#21668 Global
#4858 in USA
Share Price
$1.37
Change (1 day)
+0.00%
52-Week Range
$0.65 - $9.23
All Time High
$14.15
About

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. Its veterinary vaccines include monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. The company also develops vaccines for househol… Read more